Abstract
The pharmaceutical aspects of transfusion medicine were brought clearly into perspective in 1985 when EEC Directive number 85/374 established the rights of individuals with regard to the quality of many goods, including blood and its products. As an example of the application of this Directive, in 1987 the United Kingdom Parliament passed the Consumer Protection Act, part I of which was applicable form 1 March 1988 and introduced for the first time the concept of product liability in the field of transfusion medicine. Under this type of legislature, it is no longer necessary for an individual who has been harmed by a product to show that there had been any negligence in its production. As a consequence, most transfusion centres have now taken a structured and organized approach to quality assurance procedures, leading to the assembly of quality systems.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Wagstaff, W. (1992). The Pharmaceutical and Laboratory Aspects of Transfusion Medicine. In: Smit Sibinga, C.T., Das, P.C., Cash, J.D. (eds) Transfusion Medicine: Fact and Fiction. Developments in Hematology and Immunology, vol 27. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3504-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3504-1_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6554-9
Online ISBN: 978-1-4615-3504-1
eBook Packages: Springer Book Archive